AP-TP-V Uses, Dosage, Side Effects and more
As of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for the COVID-19 AP TP Vaccine for ‘proof of concept.’ The vaccine utilizes granulocyte macrophage-colony stimulating factor (GM-CSF), a cytokine known to enhance vaccine efficacy through prolongation of humoral and cell immunity.
| Attribute | Details |
|---|---|
| Trade Name | AP-TP-V |
| Generic | COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection |
| COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection Other Names | AP-TP-V, COVID-19 AP TP Vaccine, COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
